Biological Therapies Key Players and Leadership Alignment with Trends

Top Companies in the Biological Therapies Market

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Endo Pharmaceuticals plc (Ireland)
• Zydus Group (India)
• Bausch Health Companies Inc. (Canada)

Market Forecast

The global biological therapies market size is calculated at US$ 458.47 billion in 2024, grew to US$ 501.71 billion in 2025, and is projected to reach around US$ 1107.66 billion by 2034. The market is expanding at a CAGR of 9.35% between 2025 and 2034.

What are the Trends in the Biological Therapies Market?

Rising investment in gene and cell therapies: Gene and cell therapies are gaining attention due to their therapeutic potential in treating cancer and rare diseases. Due to this, key players and government organizations are investing in developing gene and cell therapies to provide personalized medicine.

For instance,

• In May 2025, to overcome the difficulties in producing and delivering ex vivo gene editing treatments, biotech firm Stylus Medicine raised $85 million to pioneer a new class of in vivo genetic medications.
• In March 2025, with the goal of introducing novel treatments within three years, Bharat Biotech has spent $75 million in its first cell and gene therapy laboratory in Telangana, India. The 50,000-square-foot building will be dedicated to the development of rare illness and cancer medicines.

Latest Announcements by Industry Leaders

In June 2025, recently, the Pondicherry Institute of Medical Sciences (PIMS) unveiled a new biological therapy for asthma sufferers as well as a state-of-the-art medical intensive care unit. Patients with severe eosinophilic asthma, particularly those who have long struggled with uncontrolled symptoms despite standard treatments, can have their lives significantly improved by the innovative modality with Benralizumab, according to Antonious Maria Selvam, Head of the Department of Respiratory Medicine at PIMS.

Recent Developments in the Biological Therapies Market

• In September 2025, a new firm, Kalexo Bio, has been established by US-based Aditum Bio and China-based Mabwell Bioscience to develop a novel small interfering RNA (siRNA) therapeutic, 2MW7141. Mabwell is entitled to milestone and upfront payments of up to $1 billion, as well as tiers of royalties on further global sales.
• In January 2025, with a $200 million Series A funding round, Windward Bio, a clinical-stage medication research firm specialising in severe immunological disorders, has officially launched.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com